Medicenna Therapeutics Revenue vs. Current Valuation

MDNA Stock  CAD 1.77  0.10  5.99%   
Based on Medicenna Therapeutics' profitability indicators, Medicenna Therapeutics Corp may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Medicenna Therapeutics' ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2016-06-30
Previous Quarter
0.0
Current Value
K
Quarterly Volatility
883.88347648
 
Covid
At this time, Medicenna Therapeutics' Graham Number is very stable compared to the past year. As of the 27th of November 2024, Price Book Value Ratio is likely to grow to 25.50, while Book Value Per Share is likely to drop 0.07.
For Medicenna Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Medicenna Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Medicenna Therapeutics Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Medicenna Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Medicenna Therapeutics Corp over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
Please note, there is a significant difference between Medicenna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Medicenna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medicenna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Medicenna Therapeutics Current Valuation vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Medicenna Therapeutics's current stock value. Our valuation model uses many indicators to compare Medicenna Therapeutics value to that of its competitors to determine the firm's financial worth.
Medicenna Therapeutics Corp is currently under evaluation in revenue category among its peers. It is rated top company in current valuation category among its peers . At this time, Medicenna Therapeutics' Total Revenue is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Medicenna Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Medicenna Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Medicenna Revenue vs. Competition

Medicenna Therapeutics Corp is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 0.0. Medicenna Therapeutics adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.

Medicenna Current Valuation vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Medicenna Therapeutics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
null
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Medicenna Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
98.41 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Medicenna Current Valuation vs Competition

Medicenna Therapeutics Corp is rated top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 215.55 Million. Medicenna Therapeutics totals roughly 98.41 Million in current valuation claiming about 46% of equities under Health Care industry.

Medicenna Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Medicenna Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Medicenna Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Medicenna Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Medicenna Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income19 K18.1 K
Operating Income-19.7 M-18.7 M
Net Loss-25.5 M-24.2 M
Income Before Tax-25.5 M-24.2 M
Total Other Income Expense Net-5.8 M-5.5 M
Net Loss-9 M-9.5 M
Net Loss-25.5 M-24.2 M
Income Tax Expense-10.4 M-9.9 M
Net Interest Income1.2 M1.3 M
Interest Income1.2 M1.2 M
Change To Netincome-5.8 M-5.5 M
Net Loss(0.37)(0.38)
Income Quality 0.64  1.28 
Net Loss(0.18)(0.17)

Medicenna Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Medicenna Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Medicenna Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Medicenna Therapeutics' important profitability drivers and their relationship over time.

Use Medicenna Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medicenna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medicenna Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Medicenna Therapeutics Pair Trading

Medicenna Therapeutics Corp Pair Trading Analysis

The ability to find closely correlated positions to Medicenna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medicenna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medicenna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medicenna Therapeutics Corp to buy it.
The correlation of Medicenna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medicenna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medicenna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medicenna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Medicenna Therapeutics position

In addition to having Medicenna Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Financials ETFs Thematic Idea Now

Financials ETFs
Financials ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Financials ETFs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Financials ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Medicenna Stock

To fully project Medicenna Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Medicenna Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Medicenna Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Medicenna Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Medicenna Therapeutics investors may work on each financial statement separately, they are all related. The changes in Medicenna Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Medicenna Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.